Biocept (NASDAQ:BIOC) Coverage Initiated by Analysts at assumed coverage on shares of Biocept (NASDAQ:BIOCGet Rating) in a report published on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Separately, Maxim Group lowered Biocept from a buy rating to a hold rating in a research report on Friday, April 14th.

Biocept Stock Down 0.5 %

NASDAQ BIOC opened at $1.99 on Wednesday. The firm has a market cap of $1.18 million, a PE ratio of -0.03 and a beta of 0.93. Biocept has a one year low of $1.94 and a one year high of $45.90. The stock’s 50 day simple moving average is $7.26 and its 200 day simple moving average is $13.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.91.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biocept stock. Millennium Management LLC purchased a new stake in Biocept, Inc. (NASDAQ:BIOCGet Rating) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 103,124 shares of the medical research company’s stock, valued at approximately $97,000. Millennium Management LLC owned 0.61% of Biocept as of its most recent SEC filing. 10.04% of the stock is owned by hedge funds and other institutional investors.

Biocept Company Profile

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Further Reading

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.